Table 1.
Characteristics of patients with proven/probable invasive aspergillosis according to EORTC/MSG criteria and Aspergillus PCR level
| Characteristic | EORTC/MSG criteria |
According to Aspergillus PCR level |
p | ||
|---|---|---|---|---|---|
| Without PCR | With PCR | <150 copies | ≥150 copies | ||
| No. of patients | 51 | 60 | 41 | 19 | |
| Haematologic malignancy | 13 (25.5%) | 18 (30%) | 10 (24.4%) | 5 (26.3%) | 0.87 |
| Haematopoietic stem cell transplant | 17 (33.3%) | 18 (30%) | 10 (24.4%) | 6 (31.6%) | 0.78 |
| Antifungal therapya | 0.6 | ||||
| Azole based | 36 (70.5%) | 42 (70%) | 31 (75.6%) | 11 (57.9%) | |
| Non–azole based | 13 (25.5%) | 16 (26.7%) | 10 (24.4%) | 6 (31.6%) | |
| SOT recipient | 14 (27.4%) | 16 (26.7%) | 9 (22%) | 5 (26.3%) | 0.96 |
| Other | 7 (13.7%) | 8 (13.3%) | 5 (12.2%) | 3 (15.8%) | 0.7 |
| Interval between time of sample and start of targeted antifungal therapy (mean days) | 0.65 | 0.67 | 0.8 | 0.37 | 0.7 |
| 3-month mortality | 25 (49%) | 27 (45%) | 11 (26.8%) | 16 (84.2%) | <0.0001 |
EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycosis Study Group; SOT, solid organ transplant.
a
Two patients in the >150 copies/mL group died before start of antifungal therapy.